Skip to content
Thursday 3 September 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,770.52
+0.13%
DAX
25,825.09
-0.06%
CAC 40
8,254.73
-0.31%
STOXX 50
6,347.66
-0.23%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 23 December 2020 9:44 am  |  Updated:  Wednesday 23 December 2020 9:45 am

Covid-19: R Rate creeps up to 1.4 in London according to new study

By: James Silver

Add as a preferred source on Google
GPs In England Start To Administer Covid-19 Vaccine
(Photo by Leon Neal/Getty Images)

A new study suggests the so-called R Rate for Covid-19 in the capital has crept up to 1.4.

An R Rate more than 1 means the number of those with the virus is growing.

The study, compiled by ZOE and the Covid Symptom Study app, suggests that the worst affected boroughs in London are Havering and Enfield.

Read more: How many Covid-19 cases are there in your borough?

Kingston upon Thames, Hounslow and Richmond are the least affected areas.

The ZOE study is based on around one million weekly reporters and more than 10,000 swab tests across the UK.

Tim Spector OBE, lead scientist on the ZOE COVID Symptom Study app and Professor of Genetic Epidemiology at King’s College London, said that while the “new virus strain is being blamed for the recent surge in London and the South East… there’s still no hard evidence yet to support that it is acting differently.”

London and a number of areas in the south east have been plunged into an effective lockdown, with all but essential retail and takeaways closed.

On Sunday Health Secretary Matt Hancock warned that lockdown restrictions could last until the vaccine is rolled out more widely.

The Oxford / AstraZeneca jab is expected to be approved before the end of the year.

Read more

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus

Trending Articles

  • Vodafone and Deliveroo look to patch up Reform ties after Yusuf prison threats

  • Trio of firms poised to quit London Stock Exchange as exodus gathers pace

  • Jim O’Neill: Capital gains tax hike ‘looms’ as top option for Burnham

  • Easyjet’s over-60s recruitment push is economically necessary

  • ‘Large tax hikes on the way’: How the global bond rout is boxing in Healey

More from Morning Wire

  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

    Business Wire
  • Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

    Business Wire
  • UK debt ‘hits £3 trillion’ milestone

    Economics
    Houses of Parliament in Westminster showcasing historic architecture under a clear sky, central to UK government and politics
  • Jobs market ‘stops moving’ as employment costs weigh on hirers

    Economics
    The recruitment industry is grappling with a slowdown in hiring among UK employers and wider macro-economic uncertainty.
  • e.l.f. Beauty and Parity Release “Girls Who Play Change the Game”, Connecting Girls’ Sports Participation to Long-Term Workplace Impact

    Business Wire
  • Top business group urges Healey to cut NICs to ‘solve Neets crisis’ 

    Economics
    Man in suit and red tie speaking at a podium to an audience in a modern building.
  • ‘Alice in Wonderland’ workspace firm lands £129m Aberdeen-backed finance

    Property
    Modern reception area with unique legs art installation, white desk, and colorful stools.
  • Smarsh Named to Inc. 5000 for the 19th Consecutive Year

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook